1. Home
  2. SLN vs CRAI Comparison

SLN vs CRAI Comparison

Compare SLN & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

N/A

Current Price

$19.78

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo CRA International Inc.

CRAI

CRA International Inc.

N/A

Current Price

$198.28

Market Cap

1.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
SLN
CRAI
Founded
1994
1965
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2010
1998

Fundamental Metrics

Financial Performance
Metric
SLN
CRAI
Price
$19.78
$198.28
Analyst Decision
Hold
Hold
Analyst Count
5
2
Target Price
$19.75
★ $250.50
AVG Volume (30 Days)
★ 4.3M
94.8K
Earning Date
11-24-2026
11-05-2026
Dividend Yield
N/A
★ 1.36%
EPS Growth
N/A
★ 20.77
EPS
N/A
★ 8.14
Revenue
$559,000.00
★ $751,583,000.00
Revenue This Year
N/A
$9.41
Revenue Next Year
$131.31
$4.11
P/E Ratio
★ N/A
$24.23
Revenue Growth
N/A
★ 9.33
52 Week Low
$4.19
$132.17
52 Week High
$19.87
$227.29

Technical Indicators

Market Signals
Indicator
SLN
CRAI
Relative Strength Index (RSI) 78.28 62.99
Support Level $13.01 $154.03
Resistance Level $19.87 $204.94
Average True Range (ATR) 0.07 7.87
MACD -0.10 -0.20
Stochastic Oscillator 60.42 46.65

Price Performance

Historical Comparison
SLN
CRAI

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

Share on Social Networks: